IAM Iambic Therapeutics, Inc.
Fundamentals / CIK 0001997038 / USDIambic Therapeutics, Inc. reported $332.1M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open IAM in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$252.0M Total debt: $4.89M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2025-09-30 |
|---|---|---|
| Revenue | $11.35M | $4.69M |
| Research & Development | $34.10M | $23.06M |
| Total Operating Expenses | $41.47M | $27.31M |
| Operating Income | -$30.11M | -$22.62M |
| Interest Income | $2.00M | $1.16M |
| Interest Expense | $3.0K | $4.0K |
| Income Before Tax | -$38.51M | -$21.46M |
| Income Tax Expense | $0 | $0 |
| Net Income | -$38.51M | -$21.46M |
| Basic EPS | -$8.52 | -$5.24 |
| Diluted EPS | -$8.52 | -$5.24 |
| Basic Shares Outstanding | 4.5M | 4.1M |
| Diluted Shares Outstanding | 4.5M | 4.1M |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2025-12-31 |
|---|---|---|
| Cash & Cash Equivalents | $252.0M | $180.5M |
| Cash & Short-Term Investments | $252.0M | $180.5M |
| Accounts Receivable, Net | $50.90M | $300K |
| Total Current Assets | $315.9M | $183.6M |
| Property, Plant & Equipment, Net | $9.03M | $4.83M |
| Other Non-Current Assets | $2.11M | $1.58M |
| Total Non-Current Assets | $16.16M | $11.43M |
| Total Assets | $332.1M | $195.0M |
| Accounts Payable | $4.30M | $3.32M |
| Deferred Revenue (Current) | $44.79M | $11.30M |
| Other Current Liabilities | $5.13M | $805K |
| Total Current Liabilities | $74.89M | $26.29M |
| Deferred Revenue (Non-Current) | $51.28M | $9.08M |
| Other Non-Current Liabilities | $9.0K | $91K |
| Total Non-Current Liabilities | $132.3M | $13.96M |
| Total Liabilities | $207.2M | $40.25M |
| Total Debt (incl. Leases) | $4.89M | $5.46M |
| Common Stock | $4.0K | $4.0K |
| Retained Earnings | -$283.8M | -$195.2M |
| Accumulated Other Comp. Income | $38K | $24K |
| Total Stockholders' Equity | -$269.1M | -$186.6M |
| Total Equity | -$269.1M | -$186.6M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2025-09-30 |
|---|---|---|
| Net Income | -$38.51M | -$21.46M |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2025-09-30 |
|---|---|---|
| Current Ratio | 4.22x | -- |
| Quick Ratio | 4.05x | -- |
| Revenue Growth (YoY) | +141.9% | -- |